Fed’s Powell opens door to potential rate cuts at Jackson Hole
In a challenging market environment, scPharmaceuticals Inc. (NASDAQ:SCPH) stock has recorded a new 52-week low, dipping to $3.07. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 8.08, though it’s currently trading below its Fair Value. The pharmaceutical company, known for its innovative therapies, has faced significant headwinds over the past year, reflected in a substantial 1-year change with a decline of -45.41%. Despite these challenges, the company has achieved impressive revenue growth of 303.87% in the last twelve months, and analyst price targets range from $12 to $25, suggesting potential upside. Investors have shown concern as the stock struggles to regain momentum, marking a stark contrast to its performance in the previous year. The current price level represents a critical juncture for the company as it navigates through the pressures of the healthcare market and investor expectations. Discover more comprehensive insights and 8 additional key ProTips for SCPH with an InvestingPro subscription.
In other recent news, scPharmaceuticals Inc. has announced its preliminary financial results for the fourth quarter and full year of 2024. The company expects its fourth quarter net revenue to reach between $12 million to $12.3 million, marking a significant 99% increase compared to the same period in 2023. For the full year, scPharmaceuticals anticipates net revenue to fall between $36.2 million and $36.5 million, a substantial gain of 167% over the $13.6 million reported for the full year 2023. This growth is attributed to the company’s expansion efforts, including partnerships with top Integrated Delivery Networks and hospital systems, as well as the initial impact of an expanded field sales force. The company reported shipping approximately 13,300 doses of FUROSCIX in the fourth quarter, a 23% increase from the previous quarter. scPharmaceuticals also noted an increase in the gross-to-net discount for the fourth quarter, expected to be between 18% to 19%. The company has yet to complete its financial closing procedures for the quarter and year ended December 31, 2024, and cautions that the actual results could materially differ from these preliminary results. The final and complete financial results for the fourth quarter and full year 2024 are expected to be reported in March 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.